BTI.H Stock Overview
A development stage biopharmaceutical company, engages in the research and development of products for the diagnosis and treatment of neurological diseases and disorders.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 0/6 |
Dividends | 0/6 |
Bioasis Technologies Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | CA$0.005 |
52 Week High | CA$0.01 |
52 Week Low | CA$0.005 |
Beta | 0 |
11 Month Change | n/a |
3 Month Change | n/a |
1 Year Change | -50.00% |
33 Year Change | -98.18% |
5 Year Change | -98.08% |
Change since IPO | -98.89% |
Recent News & Updates
Shareholder Returns
BTI.H | CA Biotechs | CA Market | |
---|---|---|---|
7D | 0% | -2.7% | 1.1% |
1Y | -50.0% | -40.5% | 20.6% |
Return vs Industry: BTI.H underperformed the Canadian Biotechs industry which returned -36.6% over the past year.
Return vs Market: BTI.H underperformed the Canadian Market which returned 10.4% over the past year.
Price Volatility
BTI.H volatility | |
---|---|
BTI.H Average Weekly Movement | n/a |
Biotechs Industry Average Movement | 9.7% |
Market Average Movement | 8.3% |
10% most volatile stocks in CA Market | 17.0% |
10% least volatile stocks in CA Market | 3.0% |
Stable Share Price: BTI.H has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine BTI.H's volatility change over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2006 | n/a | Deborah Rathjen | www.bioasis.us |
Bioasis Technologies Inc., a development stage biopharmaceutical company, engages in the research and development of products for the diagnosis and treatment of neurological diseases and disorders. It is developing xB3, a platform technology for the transport of therapeutic agents across the blood-brain barrier (BBB); and the treatment of central nervous system disorders (CNS), including brain cancers, and metabolic and neurodegenerative diseases. The company’s in-house development programs develop symptomatic and disease-modifying treatments for brain metastases (xB3-001), glioblastoma (xB3-002), and neurodegenerative diseases (xB3-007).
Bioasis Technologies Inc. Fundamentals Summary
BTI.H fundamental statistics | |
---|---|
Market cap | CA$397.07k |
Earnings (TTM) | -CA$2.88m |
Revenue (TTM) | CA$269.38k |
0.0x
P/S Ratio0.0x
P/E RatioIs BTI.H overvalued?
See Fair Value and valuation analysisEarnings & Revenue
BTI.H income statement (TTM) | |
---|---|
Revenue | CA$269.38k |
Cost of Revenue | CA$968.85k |
Gross Profit | -CA$699.47k |
Other Expenses | CA$2.18m |
Earnings | -CA$2.88m |
Last Reported Earnings
Nov 30, 2022
Next Earnings Date
n/a
Earnings per share (EPS) | 0 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | 0.0% |
How did BTI.H perform over the long term?
See historical performance and comparison